Boundless Bio (BOLD) EBITDA (2023 - 2026)
Boundless Bio (BOLD) posted quarterly EBITDA of -$14.5 million for Q1 2026, up 16.53% year-over-year from -$12.4 million in Q1 2025, and down 3.38% quarter-over-quarter from -$14.0 million in Q4 2025.
Boundless Bio (BOLD) EBITDA (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported EBITDA for 4 consecutive years, with -$14.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 16.53% year-over-year to -$14.5 million; the TTM figure through Mar 2026 stood at -$60.7 million (up 17.69% YoY), while the FY2025 annual figure was -$63.6 million, up 13.26% from the prior year.
- EBITDA retreated to -$14.5 million in Q1 2026 per BOLD's latest filing, from -$14.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$12.1 million in Q1 2023 and bottomed at -$19.4 million in Q2 2024.
- Historically, EBITDA has averaged -$15.9 million across 4 years, with a median of -$15.1 million in 2025.
- Annual changes were most pronounced in 2024 — EBITDA plunged 39.68% — and 2025, when it grew 23.39%.
- Boundless Bio's EBITDA stood at -$13.8 million in 2023, then sank by 32.49% to -$18.3 million in 2024, then gained by 23.39% to -$14.0 million in 2025, then decreased by 3.38% to -$14.5 million in 2026.
- Business Quant data shows BOLD's EBITDA at -$14.5 million in Q1 2026, -$14.0 million in Q4 2025, and -$15.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | -24.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.38 Mn |
| Mar 31, 2026 | -14.48 Mn |
| Dec 31, 2025 | -14.00 Mn |
| Sep 30, 2025 | -15.15 Mn |
| Jun 30, 2025 | -17.06 Mn |
| Mar 31, 2025 | -17.34 Mn |
| Dec 31, 2024 | -18.28 Mn |
| Sep 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -19.39 Mn |
| Mar 31, 2024 | -16.88 Mn |
| Dec 31, 2023 | -13.80 Mn |
| Sep 30, 2023 | -14.95 Mn |
| Jun 30, 2023 | -13.96 Mn |
| Mar 31, 2023 | -12.09 Mn |